Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Colorectal Cancer

28-Dec-2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with colorectal cancer. ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. This clinical ...

Abgenix Introduces Enhanced Version of XenoMouse Technology

05-Dec-2001 - Abgenix, Inc. announced today at the IBC Antibody Engineering Conference in San Diego, Calif., the launch of new versions of XenoMouse® mice that produce fully human monoclonal antibodies that contain both lambda and kappa light chains. Other transgenic mouse technologies in the commercial ...

Abgenix Acquires Rights To Novel Cancer Target

27-Nov-2001 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has exclusively in-licensed from Duke University Medical Center and Johns Hopkins University a potential new target for the treatment of cancer. This target, known as EGFrvIII, is a member of the family of epidermal growth factor receptors. ...

Abgenix Announces CEO Succession Plan

Ray Withy to Become CEO in Mid-2000

20-Nov-2001 - FREMONT, Calif., November 19, 2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today plans for Raymond Withy, Ph.D., to succeed R. Scott Greer as the company?s chief executive officer effective in mid-2002, and to join the company?s board of directors, effective immediately. Mr. Greer, who will ...

Abgenix And Agensys Enter Technology License Collaboration To Discover And Develop Human Therapeutic Antibodies Against Cancer

15-Aug-2001 - Abgenix, Inc. (Nasdaq: ABGX) and Agensys, Inc., a privately-held biotechnology company, announced today a research collaboration, option and license agreement under which the parties will use Abgenix’s human antibody technologies to discover and develop fully human monoclonal antibody ...

Abgenix Announces Initiation of Phase II Clinical Trial of ABX-EGF in Non-Small Cell Lung Cancer

01-Aug-2001 - Abgenix, Inc. (Nasdaq: ABGX) announced today the initiation of a Phase II clinical trial of ABX-EGF in patients with non-small cell lung cancer (NSCLC). ABX-EGF is a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor ...

Abgenix Reaches Milestone In Antibody Collaboration With Amgen,

11-Jul-2001 - Abgenix, Inc. (NASDAQ: ABGX) today announced that Amgen Inc. (Amgen) has advanced into clinical trials a fully human antibody generated with Abgenix’s technology. This milestone triggers an undisclosed payment to Abgenix. "We are pleased with the productivity of our collaboration with Amgen, ...

MDS Proteomics And Abgenix Announce Exclusive Agreement To Develop Proteomic-Based Antibody Therapies,

09-Jul-2001 - MDS Proteomics, a leading proteomics-based drug discovery company, and Abgenix, Inc. (Nasdaq: ABGX), an antibody-based biopharmaceutical company, today announced a collaboration to develop and commercialize antibody drugs. Leveraging MDS Proteomics’ proprietary proteomics systems and Abgenix’ ...

Abgenix Enters Xenomouse™ Technology Collaboration With Biogen To Generate Fully Human Antibodies

15-Jun-2001 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has signed a research collaboration, option and license agreement with Biogen, Inc. under which the parties will use Abgenix’s XenoMouse ™ technology to generate fully human monoclonal antibodies to up to fifteen antigen targets supplied by ...

Tolerability Demonstrated by ABX-EGF as Monotherapy in Advanced Cancers

15-May-2001 - Researchers presented preliminary results from a Phase 1 clinical trial of ABX-EGF, the only fully human monoclonal antibody in development against the epidermal growth factor receptor (EGFr), a receptor identified in many solid tumor types. Co-developed by Abgenix, Inc. (Nasdaq: ABGX) and ...